Related Experiment Video
Updated: Jan 22, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Modulating proteoglycan receptor PTPσ using intracellular sigma peptide improves remyelination and functional
Parvin Niknam1, Mohammad Reza Raoufy1, Yaghoub Fathollahi1
1Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract:
Multiple sclerosis (MS) is an autoimmune disease characterized by myelin and axonal damage in the central nervous system (CNS). Glial scar which is a hallmark of MS contains repair inhibitory molecules including chondroitin sulfate proteoglycans (CSPGs). CSPGs inhibit repair of damaged area through various receptors including protein tyrosine phosphatase sigma (PTPσ). In the current study we use intracellular sigma peptide (ISP), an inhibitor of PTPσ signaling, in LPC-induced focal demyelination of mouse optic chiasm. ISP treatment resulted in decreased demyelination, reduced astrogliosis, and increased newly generated oligodendrocytes which subsequently led to enhanced remyelination. Analyzing of electrophysiological (as performed by visual evoked potential recording) and behavioral (performed by visual cliff test) outcomes showed that ISP-treatment improved the integrity of optic pathway as well as the visual acuity. When ISP was administrated only during the repair phase, histological, electrophysiological and behavioral studies showed its regenerative effect. Our results demonstrated the possibility of using ISP as a new strategy to inhibit PTPσ for myelin protection, myelin repair in demyelinated axons, and functional neural pathway conductivity restoration in patients suffering from MS.
Insights
Intracellular sigma peptide (ISP) inhibits PTPσ signaling, reducing demyelination and astrogliosis in multiple sclerosis models. This promotes myelin repair and restores visual function, offering a new therapeutic strategy for CNS repair.
Area of Science:
- Neuroscience
- Immunology
- Regenerative Medicine
Background:
- Multiple sclerosis (MS) involves central nervous system (CNS) damage, with glial scars containing chondroitin sulfate proteoglycans (CSPGs) inhibiting repair.
- CSPGs impede repair by signaling through receptors like protein tyrosine phosphatase sigma (PTPσ).
Purpose of the Study:
- To investigate the therapeutic potential of intracellular sigma peptide (ISP), a PTPσ inhibitor, in a mouse model of demyelination relevant to MS.
- To evaluate ISP's effects on myelin repair, glial scarring, and functional recovery in the optic pathway.
Main Methods:
- Induced focal demyelination in the mouse optic chiasm using lysophosphatidylcholine (LPC).
- Administered ISP to assess its impact on demyelination, astrogliosis, oligodendrocyte regeneration, and remyelination.
- Evaluated functional recovery using electrophysiological (visual evoked potential) and behavioral (visual cliff test) assessments.
Main Results:
- ISP treatment significantly decreased demyelination and astrogliosis.
- ISP administration increased the generation of new oligodendrocytes, leading to enhanced remyelination.
- Electrophysiological and behavioral tests demonstrated improved optic pathway integrity and visual acuity with ISP treatment.
- ISP showed regenerative effects even when administered solely during the repair phase.
Conclusions:
- ISP effectively inhibits PTPσ signaling, promoting myelin protection and repair in demyelinated axons.
- ISP demonstrates potential as a novel therapeutic strategy for restoring neural pathway conductivity and visual function in MS patients.
- Targeting PTPσ with ISP offers a promising approach for CNS repair in demyelinating diseases.
Related Concept Videos
Proteoglycans
Intracellular Hormone Receptors
Internal Receptors
Matrix Proteoglycans and Glycoproteins
Intracellular Signaling Cascades
Peptide Bonds

